The objective of the proposed research is to elucidate the mechanisms of inactivation, degradation, and turnover of neuronal nitric oxide synthase (NOS), a cytochrome P450-like hemoprotein, caused by exposure to xenobiotics, including drugs and environmental toxicants. The central hypothesis is that such effects diminish the ability to form NO, an important bioregulatory molecule involved in many physiological functions, and cause some forms of chemically-induced toxicities. They has been shown that certain xenobiotics, such as CBrCl3, can irreversibly inactivate the neuronal isoform of NOS in a time- and metabolism-dependent manner, similar to that found for this compound with liver microsomal cytochrome P450. Protection of NOS from inactivation is afforded by the L-, but not the D-, isomer of arginine suggesting an active site directed event. More recently it was shown that guanabenz (WytesinTM), an antihypertensive agent, inactivates penile neuronal NOS in vitro in a similar metabolism dependent manner and causes a loss of penile NOS protein and activity in vivo at pharmacologically relevant doses. This may be important since NO plays a key role in penile erection and since many antihypertensive agents, including guanabenz, are known to cause impotence as a toxic side effect. Thus, the aims of the current proposal are to understand how neuronal NOS is inactivated and how the steady state levels of NOS are subsequently affected. Guanabenz will be used as a model agent to develop methods for further study of other similarly toxic agents.
The specific aims are: (1) To determine the molecular mechanism of the inactivation caused by guanabenz with the use of purified recombinantly expressed neuronal NOS. (2) To characterize the decrease in the steady state levels of neuronal NOS caused by guanabenz in the T cell hybridoma 2B4 line. (3) To more fully characterize the effects of long term administration of guanabenz on NOS in vivo. (4) To utilize the in vitro, in vivo, and T cell line as they are developed to test other biomedically important chemicals, based on a computer based structure search as well as incidence of impotence, such as debrisoquin and bethanidine. These studies should lead to a better understanding of how drugs inactivate and regulate neuronal NOS, as well as the nature of the active site of the enzyme, and thereby lead to the design of safer drugs without undesired toxicological side effects, such as impotence. Conversely, the same knowledge could be used to design more effective inhibitors of NOS for pharmacological use in a variety of neurological diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Research Project (R01)
Project #
1R01ES008365-01A1
Application #
2408847
Study Section
Special Emphasis Panel (ZRG4-ALTX-1 (01))
Project Start
1997-08-01
Project End
2001-07-31
Budget Start
1997-08-01
Budget End
1998-07-31
Support Year
1
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Pharmacology
Type
Schools of Medicine
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Lowe, Ezra R; Everett, Andrew C; Lau, Miranda et al. (2007) Naturally occurring neuronal NO-synthase inactivators found in Nicotiana tabacum (Solanaceae) and other plants. Phytomedicine 14:344-52
Dunbar, Anwar Y; Jenkins, Gary J; Jianmongkol, Suree et al. (2006) Tetrahydrobiopterin protects against guanabenz-mediated inhibition of neuronal nitric-oxide synthase in vitro and in vivo. Drug Metab Dispos 34:1448-56
Thomas, Monzy; Harrell, Jennifer M; Morishima, Yoshihiro et al. (2006) Pharmacologic and genetic inhibition of hsp90-dependent trafficking reduces aggregation and promotes degradation of the expanded glutamine androgen receptor without stress protein induction. Hum Mol Genet 15:1876-83
Lee, Anthony J; Noon, Kathleen R; Jianmongkol, Suree et al. (2005) Metabolism of aminoguanidine, diaminoguanidine, and NG-amino-L-arginine by neuronal NO-synthase and covalent alteration of the heme prosthetic group. Chem Res Toxicol 18:1927-33
Kamada, Yasuhiko; Jenkins, Gary J; Lau, Miranda et al. (2005) Tetrahydrobiopterin depletion and ubiquitylation of neuronal nitric oxide synthase. Brain Res Mol Brain Res 142:19-27
Morishima, Yoshihiro; Peng, Hwei-Ming; Lin, Hsia-lien et al. (2005) Regulation of cytochrome P450 2E1 by heat shock protein 90-dependent stabilization and CHIP-dependent proteasomal degradation. Biochemistry 44:16333-40
Draganov, Dragomir I; Teiber, John F; Speelman, Audrey et al. (2005) Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 46:1239-47
Lowe, Ezra R; Everett, Andrew C; Lee, Anthony J et al. (2005) Time-dependent inhibition and tetrahydrobiopterin depletion of endothelial nitric-oxide synthase caused by cigarettes. Drug Metab Dispos 33:131-8
Dunbar, Anwar Y; Kamada, Yasuhiko; Jenkins, Gary J et al. (2004) Ubiquitination and degradation of neuronal nitric-oxide synthase in vitro: dimer stabilization protects the enzyme from proteolysis. Mol Pharmacol 66:964-9
Peng, Hwei-Ming; Morishima, Yoshihiro; Jenkins, Gary J et al. (2004) Ubiquitylation of neuronal nitric-oxide synthase by CHIP, a chaperone-dependent E3 ligase. J Biol Chem 279:52970-7

Showing the most recent 10 out of 28 publications